Lack of receptor activator of nuclear factor-κB ligand (RANKL) expression and functional production by human multiple myeloma cells

Haematologica

Volumn 90, Issue 2, 2005, Pages 275-278

  Giuliani, Nicola ^a   Colla, Simona ^a   Morandi, Francesca ^a   Barille Nion, Sophie ^b   Rizzoli, Vittorio ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b INSERM   (France)

Author keywords

Multiple myeloma; RANKL

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR;

ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOCLAST; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

CARRIER PROTEINS; CELL LINE, TUMOR; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; OSTEOCLASTS; PROTEIN ISOFORMS; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; UP-REGULATION;

EID: 14344256115     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 2001;98:3527-33.
2. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S, et al. Human myeloma cells stimulate the receptor activator of nuclear factor-k B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002;100:4615-21.
3. Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 2001; 98:11581-6.
4. Lai FP, Cole-Sinclair M, Cheng WJ, Quinn JM, Gillespie MT, Sentry JW, et al. Myeloma cells can directly contribute to the pool of RANKL in bone bypassing the classic stromal and osteoblast pathway of osteoclast stimulation. Br J Haematol 2004;126:192-201.
5. Heider U, Zavrski I, Jakob C, Bangeroth K, Fleissner C, Langelotz C, et al. Expression of receptor activator of NF-kB ligand (RANKL) mRNA in human multiple myeloma cells. J Cancer Res Clin Oncol 2004;130:469-74.
6. Farrugia AN, Atkins GJ, To LB, Pan B, Horvath N, Kostakis P, et al. Receptor activator of nuclear factor-kB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 2003;63:5438-45.
7. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, et al. Expression of receptor activator of nuclear factor kB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res 2003;9:1436-40.
8. Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der School E, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR): a Europe against cancer program. Leukemia 2003;17:2474-86.
9. Livak K-J, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-DD C(T)) method. Methods 2001;25:402-8.
10. Nicholson GC, Malakeliis M, Collier FM, Cameron PU, Holloway WR, Gough TJ, et al. Induction of osteoclasts from CD14+ human peripheral blood mononuclear cells by receptor activator of nuclear factor kB ligand (RANKL). Clin Sci (Lond) 2000;99:133-40.
11. Michigami T, Shimizu N, Williams PJ, Niewolna M, Dallas SL, Mundy GR, et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and α4β1-integrin enhances production of osteoclast-stimulating activity. Blood 2000;96:1953-60.